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Abstract We examined the expression of peroxisome prolif-
erator-activated receptors (PPARs) and the role of PPARs in
cytokine production in mouse bone marrow-derived mast cells
(mBMMCs). mBMMCs expressed PPARL strongly and Q
slightly, but not K. Activation of mBMMCs with antigen or
calcium ionophore resulted in the increased expression of PPARQ
mRNA specifically. 15-Deoxy-v12;14-prostaglandin J2 (15d-
PGJ2) and troglitazone, all PPARQ ligands, attenuated the
antigen-induced cytokine production by mBMMCs. Carbapros-
tacyclin, a PPARL ligand, also inhibited cytokine production,
whereas PPARK ligands did not. These results suggest that
PPARL and Q might be included in the negative regulation of
mast cell activation.
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1. Introduction
Mast cell plays a pivotal role in allergic in£ammation by
releasing chemical mediators, such as histamine and lipid me-
diators including peptidyl leukotrienes, prostaglandins, and
platelet-activating factor, in response to antigen or to neuro-
peptides released from peripheral neurons [1]. In addition,
mouse mast cells produce several cytokines including tumor
necrosis factor K (TNFK), interleukin-4 (IL-4), IL-5 and gran-
ulocyte macrophage colony-stimulating factor (GM-CSF),
which act in the late phase of allergic reactions by recruiting
in£ammatory cells into the reaction site [2^5]. Furthermore,
¢brogenic cytokines such as transforming growth factor L
(TGFL), basic ¢broblast growth factor (bFGF), and plate-
let-derived growth factor (PDGF) derived from mast cells
have been thought to contribute to the pathogenesis of tissue
¢brosis [6^8].
Peroxisome proliferator-activated receptor (PPAR) is a
member of the nuclear receptor superfamily. Three di¡erent
subtypes of PPAR (K, L/N, and Q) have been described [9,10].
PPARK is expressed dominantly in liver and has been focused
in its role in lipid metabolism [11]. On the other hand, PPARQ
is found in adipose tissue, spleen, and other tissues [12] and
has been implicated in adipocyte di¡erentiation [13] and glu-
cose metabolism [14,15].
We hypothesized that PPAR is a candidate of a negative
regulator of mast cell activation, because PPARQ has been
demonstrated to modulate the activation of macrophages
[16,17]. To con¢rm our hypothesis, we examined the expres-
sion of PPARs and the e¡ect of PPAR ligands on the function
of mouse bone marrow-derived mast cells (mBMMCs).
2. Materials and methods
2.1. Chemicals
15-Deoxy-v12;14-prostaglandin J2 (15d-PGJ2), and carbaprostacy-
clin were purchased from Cayman Chemical Co. (Ann Arbor, MI,
USA). 5,8,11,14-Eicosatetraynoic acid (ETYA) and benza¢brate were
from Sigma Chemical Co. (St. Louis, MO, USA). Troglitazone was
obtained from Sankyo Co. These drugs were dissolved in ethanol,
with the ¢nal concentration of ethanol being 0.5%. This concentration
had no e¡ect on any experiment described in this paper.
2.2. Cell culture
mBMMCs were obtained as previously described [18] with some
modi¢cations. Brie£y, bone marrow cells obtained from 2-month-
old female BALB/c mice (Charles River Japan Inc., Yokohama, Ja-
pan) were cultured at a density of 1U105 cells in 1 ml in RPMI 1640
medium (GIBCO RBL, Life Technologies Inc, Gaithersburg, MD,
USA) supplemented with 10% heat-inactivated fetal calf serum
(FCS, GIBCO RBL) and 4 ng/ml recombinant mouse IL-3 (Pepro
Tech EC Inc., London, UK) at 37‡C in a humidi¢ed atmosphere
containing 5% CO2. The culture medium was changed weekly.
mBMMCs were obtained after 5 weeks of culture. The purity of the
mast cell population was determined by toluidine blue and May-
Gruenwald and Giemsa staining.
Rat peritoneal mast cells (RPMCs) were obtained from Sprague
Dawley male rats (Charles River Japan, Inc.) weighing 400^500 g.
The RPMCs were puri¢ed from rat peritoneal cells by sedimentation
through isotonic Percoll solution [19].
2.3. Stimulation of cells
For antigen stimulation, mast cells were sensitized with 10 Wg/ml of
anti-TNP mouse IgE (Pharmingen, San Diego, CA, USA) at 37‡C for
12 h. The sensitized cells were then washed, and stimulated with 20
ng/ml DNP-BSA (LSL Ltd., Tokyo, Japan) as antigen at 37‡C. Sev-
eral concentrations of drugs were added to the cells simultaneously
with IgE and incubated at 37‡C for 12 h. No cytotoxicity was ob-
served following these treatments, as estimated by trypan blue exclu-
sion.
For A23187 stimulation, A23187 was added to cells at a concen-
tration of 0.1 Wg/ml, and incubation was carried out at 37‡C.
2.4. Analysis of the mRNA expression by reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from mBMMCs with an RNA extraction
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kit (QIAGEN Inc., Valencia, CA, USA). cDNA was synthesized from
100^500 ng of total RNA by use of random hexamers (¢rst-strand
cDNA synthesis kit, Amersham Pharmacia Biotech Inc., Piscataway,
NJ, USA). cDNA (20 ng of total RNA) was ampli¢ed with the
following speci¢c primers: mouse TNFK, ATG-AGC-ACA-GAA-
AGC-ATG-ATC (upstream) and TAC-AGG-CTT-GTC-ACT-CGA-
AYY (downstream) [20]; mouse glyceraldehyde-3-phosphate dehydro-
genase (G3PDH), ATG-CCC-CAT-GTT-TGT-GAT-G (upstream)
and ATG-GCA-TGG-ACT-GTG-GTC-AT (downstream) [21];
mouse PPARK, CCT-GCA-GAG-CAA-CAA-TCC-AG (upstream)
and CCC-GTT-ATT-TAA-TGG-CGA-A (downstream) [22] ; mouse
PPARL, GTC-ATG-GAT-CCG-CCA-CAG-GAG-GAG-ACC-CCT
(upstream) and (downstream) [10]; mouse PPARQ, GAG-ATG-
CCA-TTC-TGG-CCC-ACC-AAC-TTC-GGA (upstream) and TAT-
CAT-AAA-TAA-GCA-TCA-ATC-GGA-TGG-TTC (downstream)
[10]; mouse GM-CSF, GAA-AGG-CTA-AGG-TCC-TGA-GGA-G
(upstream) and TAA-GGC-TGT-CTA-TGA-AAT-CCG (down-
stream) [23]. We detected PPARK, L, and Q with these primers for
PPARs in mouse liver, brain, and spleen, respectively. The primers for
mouse IL-4 and IL-5 were obtained from Clontech Laboratories, Inc.
(Palo Alto, CA, USA). Taq polymerase was purchased from Takara
Shuzo Co. (Tokyo, Japan). Each PCR cycle was composed of dena-
turation at 95‡C for 30 s, annealing at 55‡C for 30 s and extension at
72‡C for 2 min. The PCR products were visualized by agarose gel
electrophoresis followed by ethidium bromide staining.
2.5. Measurement of TNFK and GM-CSF by enzyme-linked
immunosorbent assay (ELISA)
mBMMCs (1U105) in culture medium were stimulated with antigen
as described above. The supernatants were collected and analyzed by
ELISA kits: Duo Sets for mouse TNFK (Genzyme Diagnostics, Cam-
bridge, MA, USA) and Quantikine mouse GM-CSF Immunoassay for
GM-CSF (R and D Systems, Inc., Minneapolis, MN, USA).
2.6. Histamine release
The sensitized cells (1U105) were suspended in physiological saline
solution (154 mM NaCl, 2.7 mM KCl, 0.9 mM CaCl2, 5 mM HEPES
and 0.1% glucose), and stimulated with 20 ng/ml DNP-BSA at 37‡C
for 30 min. After centrifugation, histamine contents of both the super-
natants and the cell pellets were determined by histamine autoanalyzer
(Bran Luebbe Analyzing Technologies, Tokyo, Japan). Then the per-
cent release was calculated.
2.7. Immunoblot analysis
The protein contents of the cell homogenates were determined with
a using BCA protein assay kit (Pierce, Rockford, IL, USA). Twenty
micrograms of protein was separated by 10^20% polyacrylamide gel
(ATTO, Tokyo, Japan) and transferred to a polyvinylidene di£uoride
membrane (Millipore Co., Bedford, MA, USA). To detect the PPARQ
protein, we used a rabbit polyclonal antibody against PPARQ (Santa
Cruz, CA, USA). This antibody is not cross-reactive with PPARK or
PPARL. Immunoreactive protein was visualized by using a detection
reagent for alkaline phosphatase (Pierce).
3. Results
3.1. Expression of PPARs in mBMMCs
Expression of PPARK, L and Q mRNA in mBMMCs
was examined by RT-PCR. mBMMCs expressed PPARL
mRNA constitutively, whereas PPARQ mRNA was detected
only slightly and PPARK not at all (Fig. 1A). Stimulation
of mBMMCs with antigen resulted in a time-dependent
increase in the mRNA level of PPARQ, with the peak at
4 h after the stimulation. A23187 also induced PPARQ
mRNA, and the highest level was observed 8 h after the
stimulation. These stimulants had no e¡ect on the expression
of PPARK or L mRNA. The induction of PPARQ was
also observed in RPMCs (Fig. 1C), which expressed PPARL
but not PPARK, as in the case of mBMMCs (data not
shown).
PPARQ protein was also detected by immunoblot analysis,
by which the induced expression was observed after antigen or
A23187 stimulation (Fig. 1B).
3.2. PPAR ligands inhibit cytokine production and histamine
release
To investigate a possible role of PPARs in mast cell, we
examined the e¡ects of PPAR ligands on the induction of
TNFK in antigen-stimulated mBMMCs. 15d-PGJ2, which
was reported to activate PPARQ [24], inhibited TNFK produc-
tion in a dose-dependent manner over a range of 1^10 WM
(Fig. 2A). The IC50 value of 15d-PGJ2 was 6.5 WM. With
troglitazone, a relatively higher concentration was required
to suppress TNFK production (IC50 = 68.2 WM). Carbaprosta-
cyclin, a PPARL ligand, also inhibited the production of
TNFK at 1 WM, whereas ETYA and beza¢brate, PPARK
agonists, did not do so even at 100 WM (Fig. 2B). GM-CSF
production was also attenuated by these PPARQ ligands, of
which e¡ects were observed at relatively lower concentrations
(Fig. 2C). The IC50 values of 15d-PGJ2 and troglitazone were
less than 1 WM and 12.8 WM, respectively.
These suppressive e¡ects of PPARQ and L ligands were
observed at the mRNA level. Induced expression of TNFK
mRNA after the antigen stimulation was lowered by 15d-
PGJ2, troglitazone and carbaprostacyclin (Fig. 3), suggesting
that PPAR ligands suppressed the transcription of the TNFK
Fig. 1. Expression of PPARs in mBMMCs. A: mBMMCs were
stimulated with 10 ng/ml DNP-BSA or 0.1 Wg/ml A23187 for 0^8 h.
Total RNA was extracted and analyzed by RT-PCR. B: Immuno-
blot analysis of PPARQ protein. mBMMCs were stimulated for 6 or
12 h as described. Cell homogenates (20 Wg protein) were separated
on SDS^PAGE and probed with anti-PPARQ antibody. A homoge-
nate of mouse spleen (m.s., 20 Wg protein) was used as a positive
control. C: PPARQ mRNA expression in RPMCs analyzed by RT-
PCR.
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gene. The induction of mRNAs of GM-CSF, IL-4 and IL-5
was observed 4 h after the antigen stimulation, and was also
reduced by 15d-PGJ2, troglitazone and carbaprostacyclin, but
not by beza¢brate.
In addition, PPARL and Q ligands also inhibited antigen-
induced histamine release, whereas beza¢brate had little e¡ect
on it (Fig. 4).
4. Discussion
In this study, we found that PPARL and Q, but not K, are
expressed in mouse mast cell. In addition, PPARQ was in-
duced in antigen- or A23187-stimulated mast cells. The ex-
pressions of PPARL and Q were also observed in rat mast
cells. However, the role of PPARs in mast cell still remains
unknown. To investigate a possible role of PPARs in mast
cell, we examined the e¡ects of PPAR ligands on the function
of mBMMCs. Mast cell is known as a major cytokine-pro-
ducing cell at the site of allergic in£ammation [2^5].
Anti-in£ammatory corticosteroid and an immunosuppres-
sive drug cyclosporin A are reported to suppress the produc-
tion of cytokines not only by lymphocytes, but also by mast
cells [25], resulting in a reduced level of allergic in£ammation.
Recent studies have shown that PPARQ negatively regulates
the production of in£ammatory cytokines and nitric oxide
synthetase by the mechanism of interrupting other transcrip-
tion factors in human macrophages [17,18]. As shown in this
paper, PPARL and Q ligands suppressed antigen-induced cy-
tokine production by mBMMCs at both protein and mRNA
levels, whereas PPARK ligands did not. These results sug-Fig. 2. E¡ects of PPAR ligands on cytokine production by
mBMMCs. mBMMCs were stimulated with 10 ng/ml DNP-BSA at
37‡C for 6 h (TNFK, A and B) or 24 h (GM-CSF, C). Spontaneous
and induced production of TNFK were 0.05 and 7.50 ng/106 cells,
respectively. Those of GM-CSF were less than 0.03 and 0.145 ng/
106 cells, respectively. A, C: PPARQ ligands, 1^10 WM 15d-PGJ2
(open circle) and 10^100 WM troglitazone (open triangle). B: PPARK
ligands, 1^100 WM beza¢brate (closed triangle) and ETYA (closed
square), and L ligand, 1^10 WM carbaprostacyclin (closed circle).
Each point represents the mean þ S.D. of triplicate experiments.
Fig. 3. E¡ects of PPAR ligands on the expression of cytokine
mRNAs. mBMMCs were treated at 37‡C for 12 h with 10 WM 15d-
PGJ2 (lane 3), 50 WM troglitazone (lane 4), 10 WM carbaprostacyclin
(lane 5), 100 WM beza¢brate (lane 6) or vehicle (lanes 1, 2). These
cells were stimulated with antigen (lanes 2^6) for 1 h (TNFK) or 4 h
(GM-CSF, IL-4 and IL-5) or not (lane 1), and then analyzed by
RT-PCR.
Fig. 4. E¡ects of PPAR ligands on histamine release from
mBMMCs. mBMMCs were sensitized with IgE and treated with
drugs as described in the text. Cells were stimulated with 10 ng/ml
DNP-BSA at 37‡C for 30 min. The concentrations of PPAR ligands
are indicated in parentheses (WM). Data are expressed as
means þ S.D. of triplicate experiments.
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gested that PPARL and Q might be involved in the negative
regulation of cytokine production in mast cell and that a li-
gand of PPAR might be a candidate of a new therapeutic
drug for allergic disorders.
However, it is uncertain whether the action of 15d-PGJ2
and troglitazone is mediated by PPARQ, because the level of
PPARQ expression was very low in the mBMMC used in this
study. Nevertheless, a small amount of PPARQ in the mast cell
may be enough to mediate the inhibitory action of these li-
gands. Otherwise another mechanism aside from PPARQ
might operate in mast cells. However, no receptor for 15d-
PGJ2 on the cell membrane has not yet been reported [26].
PPARQ is the only receptor that has been reported to mediate
the action of 15d-PGJ2. Furthermore, troglitazone, a speci¢c
PPARQ ligand, also attenuated the cytokine production by the
mast cell. These evidences suggest that PPARQ contributes to
the action of PPAR ligands used here at least partially. In-
duced expression of PPARQ after the activation of the mast
cell likely supports the inhibitory e¡ect of PPARQ ligands. The
observation that PPARQ ligands suppressed GM-CSF more
e¡ectively than TNFK (Fig. 2) may be due to the induced
expression of PPARQ after antigen stimulation, because the
induction of GM-CSF occurs later than that of TNFK.
Interestingly, mast cells produce PGD2 in response to spe-
ci¢c antigen [1]. 15d-PGJ2 is a metabolite of PGD2, which is
rapidly converted to v12-PGJ2 in the culture medium of
mBMMC [27]. In addition, these three prostanoids are all
PPARQ ligands [24]. These facts raise the possibility that a
negative feedback mechanism via PGD2-PPARQ pathway ex-
ists in mast cell. Namely, PGD2 (or its metabolites of PGJ2),
once produced after the activation of the mast cell, acts on
mast cell itself via PPARQ and attenuates the production of
in£ammatory cytokines. Consequently, it prevents proceeded
activation of mast cells and leads to the cessation of in£am-
matory responses.
It is reported that inhibition of inducible cyclooxygenase-2
(COX-2) resulted in exacerbated in£ammation in carragenin-
induced pleurisy in rats [28]. This result indicates the anti-
in£ammatory property of COX-2, which contribute to the
increased production of PGD2 and 15d-PGJ2. This report
seems to support our hypothesis that PGD2 and PGJ2, down-
stream metabolites of COX-2, have an anti-in£ammatory
property against mast cells via the PPARQ pathway.
In conclusion, we demonstrated that PPARL and Q are ex-
pressed in mouse mast cells. In addition, we suggested a pos-
sible role of PPARs in negative regulation of mast cell acti-
vation. Further studies are required to establish the role of
PPAR in mast cell, but this ¢nding may bring a new sight into
the mechanism of the regulation of mast cell activation.
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